Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation

Hiromichi Yamane, Nobuaki Ochi, Masayuki Yasugi, Takayuki Tabayashi, Tomoko Yamagishi, Yasumasa Monobe, Akiko Hisamoto, Katsuyuki Kiura, Nagio Takigawa

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


A 72-year-old woman was referred to our hospital with Stage IV non-small-cell lung cancer (NSCLC). Chest computed tomography revealed a mass in the upper lobe of the right lung, with pleural effusion. Cytologic examination identified adenocarcinoma cells in the right pleural effusion. Furthermore, both a deletion mutation in exon 19 and a threonine-methionine substitution mutation at position 790 in exon 20 (T790M) were detected in the epidermal growth factor receptors (EGFR) in the malignant cells. As systemic chemotherapy consisting of carboplatin and pemetrexed or erlotinib proved ineffective, docetaxel monotherapy was initiated as a third-line treatment. Following salvage chemotherapy, her Eastern Cooperative Oncology Group performance status improved from 3 to 1, with tumor regression over 5 months. To the best of our knowledge, this is the first report of successful docetaxel treatment for a patient with NSCLC harboring the T790M EGFR-activating mutation identified before treatment with EGFR tyrosine kinase inhibitors.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalOncoTargets and Therapy
Publication statusPublished - 2013


  • Docetaxel
  • EGFR mutation
  • Non-small-cell lung cancer
  • Pretreatment mutation
  • T790M

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation'. Together they form a unique fingerprint.

Cite this